|Sun Pharmaceutical Industries, India’s largest drugmaker, announced the closure of its merger with Ranbaxy Laboratories and said the integration would deliver synergies worth $250 million (about 1,500 crore) in three years.
Announcing an operational blueprint to achieve synergies through value-creation across functions,
Sun Pharma Managing Director Dilip Shanghvi informed that the company would invest about $300 million (about 1,800 crore) in research and development (R&D) this year, six-seven per cent of the combined revenue.
T he acquisition of Ranbaxy would not restrict the combined entity from making more large acquisitions, said Shanghvi. He, however, added his “most important focus” was winning the confidence of regulators.